For the first time ever, SCINTIX biology-guided radiotherapy uses the emissions from the cancer itself for live targeting of tumors at any stage.
Powered by the rapidly expanding universe of radiopharmaceuticals, the RefleXion® X1 with SCINTIX technology uses emissions for live targeting of tumors at any stage. Initially using fludeoxyglucose F18 (FDG), only SCINTIX therapy will leverage disease-specific radiopharmaceuticals as they become available.
The RefleXion X1 is designed to deliver SCINTIX therapy along with industry-leading CT-guided IMRT and SBRT. Equipped with fan-beam kVCT imaging, the X1 provides superior imaging for patient localization resulting in improved confidence for accurate dose delivery.
SCINTIX therapy makes radiotherapy an option for patients with tumors in the bone or lung at any stage of cancer. Our breakthrough technology expands treatment to hundreds of thousands of patients across the U.S.
Finally, SCINTIX therapy solves the conundrum of tumor tracking by using emissions to produce live targeting information continuously updated with sub second latency during treatment. This approach reduces the need for motion management techniques such as gating or implanted fiducials and may result in lower toxicity to healthy tissue.
Let us tell you more.
Contact UsStay up to date.
Sign Up